Regeneron Pharmaceuticals Inc

Regeneron discovers and commercializes medicines for eye diseases (EYLEA for macular degeneration), allergic conditions (Dupixent for eczema and asthma), cancer (Libtayo), and rare diseases [Yahoo Finance]. The company operates through a combination of selling FDA-approved drugs and investing heavily in research partnerships to develop next-generation treatments using technologies like gene-editing and radiopharmaceuticals [Yahoo Finance].

Regeneron Pharmaceuticals is a major biotechnology company that develops treatments for eye diseases, cancer, and rare conditions, generating $14.3B in annual revenue [Yahoo Finance]. The company recently suffered a significant setback when its experimental melanoma drug combination failed in late-stage testing, causing the stock to drop sharply [Yahoo Finance]. Despite this disappointment, Regeneron maintains a strong financial position with $4.1B in free cash flow and continues expanding through partnerships in gene-editing and oncology research [Yahoo Finance].

Regeneron is financially robust with exceptional profitability and zero net debt.